Revenue remains sporadic and immaterial at $18,700 in 2026Q1, while the company continues to report significant operating losses, including a $2.0 million deficit for the same period.
| Sales/Revenue | 40.45K | 21.8K | 0 | 0 | 233.28K | 638.04K | 1.13M | 0 |
| Revenue Growth % | - | - | - | -100% | -63.44% | -43.35% | - | - |
| Cost of Goods Sold | 4.36K | 4.23K | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | 19.41% | - | - | - | - | - | - |
| Gross Profit | 36.09K | 17.57K | 0 | 0 | 233.28K | 638.04K | 1.13M | 0 |
| Gross Margin % | 89.22% | 80.59% | - | - | 100% | 100% | 100% | - |
| Gross Profit Growth % | - | - | - | -100% | -63.44% | -43.35% | - | - |
| Operating Expenses | 9.37M | 8.93M | 3.09M | 3.87M | 3.67M | 4.55M | 2.98M | 2.18M |
| OpEx % of Revenue | - | 40953.78% | - | - | 1571.38% | 712.36% | 264.41% | - |
| Selling, General & Admin | 7.33M | 6.84M | 2.6M | 2.92M | 2.72M | 3.1M | 1.34M | 1.49M |
| SG&A % of Revenue | - | 31380.58% | - | - | 1167.23% | 485.47% | 118.67% | - |
| Research & Development | -55.7K | 2.09M | 492.66K | 954.79K | 942.81K | 1.45M | 1.64M | 685.74K |
| R&D % of Revenue | - | 9573.2% | - | - | 404.15% | 226.9% | 145.74% | - |
| Other Operating Expenses | 1000K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -9.33M | -8.91M | -3.09M | -3.87M | -3.43M | -3.91M | -1.85M | -2.18M |
| Operating Margin % | -23075.85% | -40873.19% | - | - | -1471.38% | -612.36% | -164.41% | - |
| Operating Income Growth % | - | -188.19% | 20.14% | -12.77% | 12.15% | -111.01% | 14.93% | - |
| EBITDA | -9.01M | -8.58M | -2.19M | -4.56M | -4.22M | -4.09M | -1.64M | -2.73M |
| EBITDA Margin % | -22285.99% | -39359.87% | - | - | -1807.57% | -640.44% | -145.72% | - |
| EBITDA Growth % | -187.17% | -291.5% | 52% | -8.26% | -3.19% | -148.99% | 39.88% | - |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | -9.01M | -8.58M | -2.19M | -4.56M | -4.22M | -4.09M | -1.64M | -2.73M |
| Net Interest Income | -109.38K | -66.02K | -242.81K | -218.22K | -740.24K | -113.86K | -13.5K | -317.1K |
| Interest Income | 8.04K | 0 | 5.56K | 482 | 617 | 132 | 38 | 4 |
| Interest Expense | 117.42K | 66.02K | 248.37K | 218.71K | 740.85K | 113.99K | 13.54K | 317.1K |
| Other Income/Expense | 155.73K | 263.82K | 651.66K | -912.92K | -1.53M | -293.16K | 196.9K | -870.06K |
| Pretax Income | -9.18M | -8.64M | -2.44M | -4.78M | -4.96M | -4.2M | -1.65M | -3.05M |
| Pretax Margin % | -22690.83% | -39662.77% | - | - | -2125.15% | -658.31% | -146.92% | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 179.17K | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | -4.27% | 0% | 0% |
| Net Income | -9.18M | -8.64M | -2.44M | -4.78M | -4.96M | -4.38M | -1.65M | -3.05M |
| Net Margin % | -22690.83% | -39662.77% | - | - | -2125.15% | -686.39% | -146.92% | - |
| Net Income Growth % | -175.25% | -254.35% | 49% | 3.51% | -13.2% | -164.67% | 45.69% | - |
| Net Income (Continuing) | -9.18M | -8.64M | -2.44M | -4.78M | -4.96M | -4.38M | -1.65M | -3.05M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.26 | -0.25 | -0.08 | -0.14 | -0.15 | -0.44 | -0.19 | -0.35 |
| EPS Growth % | -153.69% | -194.81% | 39.43% | 6.67% | 65.91% | -131.58% | 45.71% | - |
| EPS (Basic) | - | -0.25 | -0.08 | -0.14 | -0.15 | -0.44 | -0.19 | -0.35 |
| Diluted Shares Outstanding | 35.26M | 34.63M | 28.78M | 32.88M | 32.88M | 9.49M | 8.74M | 8.74M |
| Basic Shares Outstanding | 35.26M | 34.63M | 28.78M | 32.88M | 32.88M | 9.49M | 8.74M | 8.74M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
Imminent liquidity and dilution
As reported in recent financial filings, Jupiter Neurosciences generated a nominal $18,700 in revenue during 2026Q1, confirming the company remains in a pre-commercial stage where top-line growth is non-existent and entirely dependent on sporadic, project-based inflows rather than sustainable product sales or recurring commercial demand.
The lack of consistent revenue generation underscores the company's status as a pure-play clinical development entity. Investors should interpret these minor inflows as accounting artifacts rather than indicators of market traction, as the business model has yet to demonstrate a viable path to commercialization.
Based on the company's latest income statement, operating expenses have escalated significantly, with SG&A costs reaching $1.6 million in 2026Q1, reflecting a cost structure that is increasingly disconnected from the firm's minimal revenue base and heavily weighted toward administrative and regulatory overhead.
The rapid expansion of SG&A relative to R&D suggests that the company is incurring substantial fixed costs to maintain corporate operations despite the absence of a commercial product. This expense discipline warrants further investigation, as the current burn rate appears unsustainable without immediate external capital infusion.
According to historical income data, Jupiter Neurosciences exhibits a negative operating margin of 105.2% as of 2026Q1, indicating that the company lacks the necessary scale to achieve operating leverage and remains entirely reliant on equity financing to cover its mounting clinical and administrative obligations.
The inability to scale operating income alongside R&D investment highlights the inherent risks of a pre-revenue biotech model. Without a clear inflection point in clinical trial outcomes, the company appears trapped in a cycle of high fixed-cost consumption that continues to erode shareholder value.
While the company touts a proprietary delivery platform, the financial reality, as evidenced by the $2.0 million operating loss in 2026Q1, suggests that the firm's cash runway is dangerously thin, creating a high probability of dilutive financing that could severely impair existing equity holders.
Short-term observers may focus on the potential of the JNS101 molecule, but the income statement reveals a company struggling to manage its burn rate. The reliance on multiple concurrent Phase II trials appears to be a strategic overreach that may force a liquidity crisis before any definitive data readouts occur.
Quick answers to the most common questions about buying JUNS stock.
For fiscal year 2025, Jupiter Neurosciences, Inc. (JUNS) reported total revenue of $0.0M.
Jupiter Neurosciences, Inc. (JUNS) reported a net loss of $8.6M for the fiscal year ending 2025.
Jupiter Neurosciences, Inc. (JUNS) reported an operating income of $-8.9M, resulting in an operating profit margin of -40873.2%. This margin reflects the operational efficiency of the business before interest and taxes.
Jupiter Neurosciences, Inc. (JUNS) generated $0.0M in gross profit for the year, representing a gross profit margin of 80.6%. This demonstrates the company's core pricing power and production efficiency.